AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CalciMedica Director Rachel Leheny Buys 1000 Shares at $3.4/Share
ByAinvest
Monday, Jul 21, 2025 2:10 pm ET1min read
CalciMedica, Inc. (CALC) reports that Director and 10% Owner, as well as Chief Executive Officer, Rachel A. Leheny, has recently acquired 1000 shares of the company's stock at a price of $3.4 per share on July 21, 2025.
CalciMedica, Inc. (CALC) has reported that Director, 10% Owner, and Chief Executive Officer Rachel A. Leheny has recently acquired 1,000 shares of the company's stock at a price of $3.40 per share on July 21, 2025. This transaction, reported in a Form 4 filing with the Securities and Exchange Commission, follows a series of insider buying activities observed in the company.Leheny's purchase comes amidst a period of stock decline, with CalciMedica's shares having fallen by 46% over the past six months. Despite this, the company's market capitalization stands at approximately $22.63 million, suggesting that some investors, including Leheny, believe the stock is slightly undervalued. The transaction brings Leheny's total direct holdings to 164,706 shares, with additional indirect holdings through various entities.
CalciMedica has been active in the development of its Phase 2 KOURAGE trial for the treatment of acute kidney injury (AKI) with respiratory failure. The trial, which aims to evaluate the effectiveness of Auxora, is expected to provide data by the end of 2025. Additionally, the company has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following a merger with Moss Adams LLP. This change was approved by the company's Board of Directors' Audit Committee and was completed without any reported disagreements.
Investors should monitor insider buying activities as they can provide valuable insights into a company's prospects. While insider trading alone should not be the sole basis for investment decisions, it can be a useful indicator when combined with other fundamental and technical analysis.
References:
[1] https://www.ainvest.com/news/calcimedica-director-leheny-rachel-buys-2-47-share-2507/
[2] https://www.investing.com/news/insider-trading-news/calcimedica-calc-ceo-leheny-buys-6k-in-stock-93CH-4136776
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet